{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:13:14Z","timestamp":1792761194722,"version":"4.5.0"},"reference-count":141,"publisher":"SAGE Publications","issue":"23-24","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>Adeno-associated viruses (AAVs) are being increasingly used as gene therapy vectors in clinical studies especially targeting central nervous system (CNS) disorders. Correspondingly, host immune responses to the AAV capsid or the transgene-encoded protein have been observed in various clinical and preclinical studies. Such immune responses may adversely impact patients' health, prevent viral transduction, prevent repeated dosing strategies, eliminate transduced cells, and pose a significant barrier to the potential effectiveness of AAV gene therapy. Consequently, multiple immunomodulatory strategies have been used in attempts to limit immune-mediated responses to the vector, enable readministration of AAV gene therapy, prevent end-organ toxicity, and increase the duration of transgene-encoded protein expression. Herein we review the innate and adaptive immune responses that may occur during CNS-targeted AAV gene therapy as well as host- and treatment-specific factors that could impact the immune response. We also summarize the available preclinical and clinical data on immune responses specifically to CNS-targeted AAV gene therapy and discuss potential strategies for incorporating prophylactic immunosuppression regimens to circumvent adverse immune responses.<\/jats:p>","DOI":"10.1089\/hum.2022.138","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T12:45:20Z","timestamp":1661172320000},"page":"1228-1245","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":85,"title":["Immune Responses and Immunosuppressive Strategies for Adeno-Associated Virus-Based Gene Therapy for Treatment of Central Nervous System Disorders: Current Knowledge and Approaches"],"prefix":"10.1177","volume":"33","author":[{"given":"Suyash","family":"Prasad","sequence":"first","affiliation":[{"name":"Taysha Gene Therapies, Dallas, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Dimmock","sequence":"additional","affiliation":[{"name":"Rady Children's Institute for Genomic Medicine, Rady Children's Hospital, San Diego, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Department of Neurology, O'Donnell Brain Institute, University of Texas Southwestern, Dallas, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagdeep S.","family":"Walia","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, Department of Pediatrics, Queen's University, Kingston, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanchal","family":"Sadhu","sequence":"additional","affiliation":[{"name":"Taysha Gene Therapies, Dallas, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Tavakkoli","sequence":"additional","affiliation":[{"name":"Taysha Gene Therapies, Dallas, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald S.","family":"Lipshutz","sequence":"additional","affiliation":[{"name":"Departments of Molecular and Medical Pharmacology and Surgery, Intellectual and Developmental Disabilities Research Center at UCLA, David Geffen School of Medicine at UCLA, Los Angeles, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.885"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb5413"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2021.135"},{"issue":"3","key":"e_1_3_5_5_2","first-page":"185","article-title":"Reduced immunogenicity of intraparenchymal delivery of adeno-associated virus serotype 2 vectors: Brief overview","volume":"22","author":"Hwu WL","year":"2021","unstructured":"Hwu WL, , Muramatsu SI, , Gidoni-Ben-Zeev B. Reduced immunogenicity of intraparenchymal delivery of adeno-associated virus serotype 2 vectors: Brief overview. Curr Gene Ther, 2021; 22(3):185\u2013190.","journal-title":"Curr Gene Ther"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2988"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2019.05.005"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-S4422(21)00251-9"},{"issue":"4","key":"e_1_3_5_9_2","first-page":"24","article-title":"A systematic analysis of the immunologic effects of intrathecal AAV9 mediated gene transfer targeting the nervous system in giant axonal neuropathy","volume":"28","author":"Bharucha-Goebel DD.","year":"2020","unstructured":"Bharucha-Goebel DD. A systematic analysis of the immunologic effects of intrathecal AAV9 mediated gene transfer targeting the nervous system in giant axonal neuropathy. Mol Ther, 2020; 28:4(4) Supplement 1 (24\u201325).","journal-title":"Mol Ther"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-031413-085355"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-101416-041936"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0234-5"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2016.087"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000228"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.12.008"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2019.06.007"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407309"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120474"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.666666"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2017.146"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1484"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.72"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10020119"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2019.03.020"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2012.101"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.210"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.015"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-017-0464-2"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI66778"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100915"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.01.022"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.02.015"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/35099560"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1093620"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.02282-14"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.74.18.8732-8739.2000"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.76.24.12435-12447.2002"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.78"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120145"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1159\/000369273"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI37607"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301611"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143780"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01990-07"},{"key":"e_1_3_5_46_2","unstructured":"Food and Drug Administration Cellular Tissue and Gene Therapies Advisory Committee Meeting #70 Toxicity Risks of Adeno-associated Virus Vectors for Gene Therapy. Available from: https:\/\/www.fda.gov\/media\/151599\/download [Last accessed: September 30 2021]."},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01107-6"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.11.054"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.12.007"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.04.019"},{"key":"e_1_3_5_51_2","unstructured":"Janeway Jr. CA Travers P Walport M Shlomchik MJ. Principles of innate and adaptive immunity. In: Immunobiology: The Immune System in Health and Disease 5th ed. Garland Science: New York NY USA; 2001."},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2012.55"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2011.90"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1086\/595830"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05107-11"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00628-3"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.AID-0019-2014"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107453"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-751040"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108046"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1549"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-167510"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1358"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2018.06.014"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2014.09.008"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2011.01.015"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161208784705504"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.624988"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00670"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2014.109"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2019.100475"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2012.153"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.09.011"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2016.109"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI68205"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-021-00296-0"},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2014.0034"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112471"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2021.111549"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-370-7_6"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.235"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05375-11"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2021.124"},{"key":"e_1_3_5_84_2","unstructured":"Usman N Annamaraju P. Type III Hypersensitivity Reaction. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559122\/ [Last accessed: November 18 2021]."},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines2010080"},{"key":"e_1_3_5_86_2","doi-asserted-by":"publisher","DOI":"10.1089\/hgtb.2016.188"},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.01.002"},{"key":"e_1_3_5_88_2","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Human Gene Therapy for Neurodegenerative Diseases Draft Guidance for Industry;. 2021. Available from: https:\/\/www.fda.gov\/media\/144886\/download [Last accessed: January 18 2022]."},{"key":"e_1_3_5_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.05.018"},{"key":"e_1_3_5_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.12.001"},{"key":"e_1_3_5_91_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.648532"},{"key":"e_1_3_5_92_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.0233"},{"key":"e_1_3_5_93_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.110"},{"key":"e_1_3_5_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119142"},{"key":"e_1_3_5_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.06.003"},{"key":"e_1_3_5_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2014.51"},{"key":"e_1_3_5_97_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.026"},{"key":"e_1_3_5_98_2","article-title":"Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome [press release]","author":"Taysha Gene Therapies","year":"2022","unstructured":"Taysha Gene Therapies. Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome [press release]. Taysha Gene Therapies, March 29 2022.","journal-title":"Taysha Gene Therapies"},{"key":"e_1_3_5_99_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-021-00279-2"},{"key":"e_1_3_5_100_2","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.734878"},{"key":"e_1_3_5_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30169-2"},{"key":"e_1_3_5_102_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2011.220"},{"key":"e_1_3_5_103_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2008.022"},{"key":"e_1_3_5_104_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003454"},{"key":"e_1_3_5_105_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003640"},{"key":"e_1_3_5_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(17)30125-6"},{"key":"e_1_3_5_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70254-4"},{"key":"e_1_3_5_108_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c29356"},{"key":"e_1_3_5_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.09.004"},{"key":"e_1_3_5_110_2","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-26.5.437"},{"key":"e_1_3_5_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.05.044"},{"key":"e_1_3_5_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.001"},{"key":"e_1_3_5_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2010.04.005"},{"key":"e_1_3_5_114_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxr048"},{"key":"e_1_3_5_115_2","doi-asserted-by":"publisher","DOI":"10.5500\/wjt.v6.i1.183"},{"key":"e_1_3_5_116_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658038"},{"key":"e_1_3_5_117_2","doi-asserted-by":"publisher","DOI":"10.1191\/0961203305lu2109oa"},{"key":"e_1_3_5_118_2","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.5MIR0420-055R"},{"key":"e_1_3_5_119_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200211002-00002"},{"key":"e_1_3_5_120_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21144972"},{"key":"e_1_3_5_121_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-021-00017-7"},{"key":"e_1_3_5_122_2","unstructured":"RAYOS (prednisone) Prescribing Information. Horizon Pharma USA Inc. . 2012. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202020s000lbl.pdf [Last accessed: January 21 2022)."},{"key":"e_1_3_5_123_2","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12361"},{"key":"e_1_3_5_124_2","unstructured":"RAPAMUNE (sirolimus) Prescribing Information. Wyeth Pharmaceuticals Inc. . 2017. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021083s059 021110s076lbl.pdf [Last accessed: January 21 2022]."},{"key":"e_1_3_5_125_2","unstructured":"CELLCEPT\u00ae (mycophenolate mofetil) Prescribing Information. Genentech USA Inc. . 2021. Available from: https:\/\/www.gene.com\/download\/pdf\/cellcept_prescribing.pdf [Last accessed: January 21 2022]."},{"key":"e_1_3_5_126_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2019.08.039"},{"key":"e_1_3_5_127_2","unstructured":"PROGRAF\u00ae (tacrolimus) Prescribing Information. Astellas Pharma US Inc. 2012. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/050709s031lbl.pdf [Last accessed: January 21 2022]."},{"key":"e_1_3_5_128_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc11304"},{"key":"e_1_3_5_129_2","unstructured":"RITUXAN (rituximab) Prescribing Information. Genentech Inc. 2012. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103705s5367s5388lbl.pdf [Last accessed: January 21 2022)."},{"key":"e_1_3_5_130_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1344"},{"key":"e_1_3_5_131_2","unstructured":"SolirisTM (eculizumab) Prescribing Information. Alexion Pharmaceuticals Inc. 2007. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/125166lbl.pdf [Last accessed: January 21 2022)."},{"key":"e_1_3_5_132_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0372-x"},{"key":"e_1_3_5_133_2","unstructured":"PLAQUENIL\u00ae (hydroxychloroquine sulfate) Prescribing Information. Concordia Pharmaceuticals Inc. 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/009768s053lbl.pdf [Last accessed: January 21 2022]."},{"key":"e_1_3_5_134_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.655478"},{"key":"e_1_3_5_135_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005056"},{"key":"e_1_3_5_136_2","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2014.2514"},{"key":"e_1_3_5_137_2","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2012.43"},{"key":"e_1_3_5_138_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.04.001"},{"key":"e_1_3_5_139_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.244"},{"key":"e_1_3_5_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.05.012"},{"key":"e_1_3_5_141_2","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-122"},{"key":"e_1_3_5_142_2","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2015.109"}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2022.138","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2022.138","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2022.138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:56:21Z","timestamp":1777449381000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2022.138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":141,"journal-issue":{"issue":"23-24","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1089\/hum.2022.138"],"URL":"https:\/\/doi.org\/10.1089\/hum.2022.138","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}